Samsung Biologics Signs Pharmaceutical Contract Manufacturing Agreement Worth 112.1 Billion KRW
[Asia Economy Reporter Lee Gwan-ju] Samsung Biologics announced on the 28th that it has signed a contract for contract manufacturing organization (CMO) with the global pharmaceutical company 'Eli Lilly Kinsale Limited.' The contract amount is approximately 112.13391 billion KRW.
Hot Picks Today
"I Only Meant to Try It Once"... 30 Million Won Taken from Father's Account: Youth Caught in Gambling
- “They Used to Just Incinerate Unsold Goods”: Will Luxury Prices Finally Drop as Disposal Is Restricted?
- Apartment Building Representative Dies After Dispute... Appeals Court Also Finds 'Not Guilty' of Fatal Assault
- Woman Wins $8.5 Million Lottery After Divorce... Court Rules Ex-Husband Has No Rights
- "Zhungti Nanda? Koreans Flock to China... What’s Behind the Changing Travel Trends?"
The company stated, "The contract was initially signed on December 20, 2019, and the confirmed sales amount has increased due to the customer's increased demand," adding, "The confirmed contract amount may increase to 177.45 million USD through further negotiations with the customer."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
